Chemical characterization and hypothesis‑generating network pharmacology analysis of Shenfu Qiangxin pill
Introduction: Heart failure represents a heavy global clinical medical burden with unsatisfactory long term outcomes under conventional therapeutic regimens. Traditional Chinese medicine exerts beneficial effects for chronic heart failure management via multi-component and multi-target modes of action. Shenfu Qiangxin pill (SFQXP) is a clinically effective herbal formula for chronic heart failure treatment, yet its systematic chemical profiling and underlying molecular mechanisms remain poorly characterized.
Objective: To characterize the chemical constituents of SFQXP and generate testable hypotheses for heart failure-relevant mechanisms using ultra-high-performance liquid chromatography quadrupole orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap-HRMS), network pharmacology, and molecular docking.
Methods: In vitro extracts and rat medicated serum were analyzed using UHPLC-Q-Orbitrap HRMS. Constituents were tentatively annotated against TCM Pro 2.0 and an in-house compound library. Active compounds were screened via SwissADME. Drug-elated and heart failure-associated targets were retrieved from SwissTargetPrediction, GeneCards, and OMIM. Intersection targets were subjected to protein–protein interaction network construction, core-target filtering, and Gene Ontology/Kyoto Encyclopedia of Genes and Genomes enrichment analyses. AutoDock Vina 1.1.2 was used to evaluate molecular docking between sanggenol A and peroxisome proliferator-activated receptor gamma (PPARG).
Results: A total of 232 non-redundant constituents (186 in vitro, 151 serum-derived; 105 shared) were annotated at MSI Level 2 without authentic reference standards. Thirty-five bioactive candidates and 125 overlapping drug-disease targets were obtained, and 33 core targets were screened. Enrichment analyses highlighted cyclic guanosine monophosphate-protein kinase G, cyclic adenosine monophosphate, and calcium signaling pathways associated with ventricular remodeling. Sanggenol A exhibited favorable in silico predicted binding affinity (−8.3 kcal/mol) to PPARG.
Conclusion: This study profiles SFQXP chemical components and puts forward computational mechanistic hypotheses. Anti-heart failure bioactivity has not been experimentally validated; further cellular and animal‑model experiments are required for verification.
- Chinese Society of Cardiology, Chinese Medical Association; Chinese College of Cardiovascular Physician; Chinese Heart Failure Association of Chinese Medical Doctor Association; Editorial Board of Chinese Journal of Cardiology. Zhongguo xinli shuaijie zhenduan he zhiliao zhinan 2024 [2024 Chinese guidelines for the diagnosis and treatment of heart failure]. Chin J Cardiol. 2024;52(3):235-275. [In Chinese]. doi: 10.3760/cma.j.cn112148-20231101-00405
- Aşkin L, Tanriverdi O. The benefits of sacubitril-valsartan in low ejection fraction heart failure. Abant Med J. 2022;11(3):336-337. doi: 10.47493/abantmedj.1182158
- Sun Y. Ma Lianzhen yi Shenfu Qiangxin Wan bianzhi manxing xinshuai jingyan [Professor Ma Lianzhen's experience in differentiating and treating chronic heart failure with Shenfu Qiangxin Pill]. Chin J Basic Med Tradit Chin Med. 2012;18(7):745-746. [In Chinese]. doi: 10.19945/j.cnki.issn.1006-3250.2012.07.023
- Yuan H, Zhang DW, Ma XH. Shenfu Qiangxin Wan zhiliao xinli shuaijie youxiaoxing ji anquanxing de Meta fenxi [Efficacy and safety of Shenfu Qiangxin Pill for heart failure: a meta-analysis]. Chin J Integr Med Cardio Cerebrovasc Dis. 2021;19(16):2693-2700. [In Chinese]. doi: 10.12102/j.issn.1672-1349.2021.16.003
- Wei YQ, Liu Y, Meng ZR, et al. Shenfu Qiangxin Wan lianhe changgui liaofa zhiliao manxing xinli shuaijie de Meta fenxi [Efficacy and safety of Shenfu Qiangxin Pill combined with conventional therapy for chronic heart failure: a meta-analysis]. China Pharmacy. 2021;32(6):736-742. [In Chinese]. doi: 10.6039/j.issn.1001-0408.2021.06.16
- Ma ZY. Shenfu Qiangxin Wan duibi leimipuli zhiliao manxing chongxuexing xinlishuaijie de linchuang liaoxiao [Clinical efficacy of Shenfu Qiangxin Pill vs ramipril in chronic congestive heart failure]. Pract Clin J Integr Tradit West Med. 2023;23(14):41-43. [In Chinese]
- Zhang X, Jin Q, Zhuo XM. Shakubaqu xieshatan lianhe Shenfu Qiangxin Wan zhiliao manxing xinli shuaijie de linchuang liaoxiao [Clinical efficacy of sacubitril valsartan combined with Shenfu Qiangxin Pill in chronic heart failure]. Contemp Med. 2021;27(29):127-128. [In Chinese]
- Xiong S, Zhao YL, Han S. Shenfu Qiangxin Wan fuzhi manxing xinli shuaijie linchuang guancha [Clinical observation of Shenfu Qiangxin Pill in adjuvant treatment of chronic heart failure]. J Pract Tradit Chin Med. 2024;40(7):1299-1301. [In Chinese]
- Yang Y, Yao CL, Guo DA. Insight into chemical basis of traditional Chinese medicine based on liquid chromatography mass spectrometry. Acta Pharm Sin B. 2021;11(6):1469-1492. doi: 10.1016/j.apsb.2021.02.017
- Xia Q, Liu M, Li H, et al. Network pharmacology strategy to investigate the pharmacological mechanism of HuangQiXiXin decoction on cough variant asthma. Evid Based Complement Alternat Med. 2020;2020(1):3829092. doi: 10.1155/2020/3829092
- Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28(1):27-30. doi: 10.1093/nar/28.1.27
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461. doi: 10.1002/jcc.21334
- Hsin KY, Ghosh S, Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS One. 2013;8(12):e83922. doi: 10.1371/journal.pone.0083922
- Xu H, Wang W, Li X, et al. Botany, traditional use, phytochemistry, pharmacology and clinical applications of rhubarb (Rhei Radix et Rhizome): a systematic review. Am J Chin Med. 2024;52(7):1925-1967. doi: 10.1142/S0192415X24500757
- Wu Z, Qian J, Feng C, et al. A review of Aconiti Lateralis Radix Praeparata (Fuzi) for kidney disease: phytochemistry, toxicology, herbal processing, and pharmacology. Front Pharmacol. 2024;15:1427333. doi: 10.3389/fphar.2024.1427333
- Li Y, Wang H, Zhang Y. Exploring the therapeutic and antitumor properties of morusin: a review of recent advances. Front Mol Biosci. 2023;10:1168298. doi: 10.3389/fmolb.2023.1168298
- Evans LW, Ferguson BS, McKinsey TA. Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy. J Nutr Biochem. 2020;79:108339. doi: 10.1016/j.jnutbio.2019.108339
- Wang Z, Li Y, Zhang L. Unlocking ginsenosides' therapeutic power with polymer-based delivery systems: current applications and future perspectives. Front Pharmacol. 2025;16:1629803. doi: 10.3389/fphar.2025.1629803
- Li Y, Jiang JG. Health functions and structure-activity relationships of natural anthraquinones from plants. Food Funct. 2018;9(12):6063-6080. doi: 10.1039/C8FO01569D
